

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P O Box 1450 Alexandria, Virgiria 22313-1450 www.uspio.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/446,996	12/30/1999	JOHANNES CHRISTIANUS VAN GROENINGHEN	49477(1958)	3246
26181 7590 FISH & RICHARDSON P.C. PO BOX 1022			EXAMINER	
			BORGEEST, CHRISTINA M	
MINNEAPOL	IS, MN 55440-1022		ART UNIT	PAPER NUMBER
			1649	
			MAIL DATE	DELIVERY MODE
		,	03/06/2008	PAPER

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Applicant(s)		
VAN GROENINGHEN, JOHANNES CHRISTIANUS		
Art Unit		
1649		
	/AN GROENINGHE CHRISTIANUS Art Unit	

-	Examine	AILOIIL				
	Christina Borgeest	1649				
The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence add	ress			
THE REPLY FILED 04 February 2008 FAILS TO PLACE THIS	APPLICATION IN CONDITION FO	R ALLOWANCE.				
<ol> <li>W The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance, (2) a Notice of Appl for Continued Examination (RCE) in compliance with 37 C periods:</li> </ol>	the same day as filing a Notice of a replies: (1) an amendment, affidavit eal (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request			
a) The period for reply expires 6 months from the mailing date	of the final rejection.					
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire land.	ater than SIX MONTHS from the mailing	date of the final rejection	n.			
Examiner Note: If box 1 is checked, check either box (a) or ( MONTHS OF THE FINAL REJECTION. See MPEP 706.07(		FIRST REPLY WAS FI	LED WITHIN TWO			
Extensions of time may be obtained under 37 CFR 1.136(a). The date wave been filed is the date for purposes of determining the period of lex under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	on which the petition under 37 CFR 1.1: tension and the corresponding amount of shortened statutory period for reply origit than three months after the mailing date	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as			
2. The Notice of Appeal was filed on 04 February 2008. A b	rief in compliance with 37 CFR 41.3	37 must be filed within	two months of			
the date of filing the Notice of Appeal (37 CFR 41.37(a)), appeal. Since a Notice of Appeal has been filed, any reply	or any extension thereof (37 CFR 4	1.37(e)), to avoid disr	nissal of the			
AMENDMENTS						
<ol> <li>The proposed amendment(s) filed after a final rejection, I</li> </ol>			cause			
<ul> <li>(a) ☐ They raise new issues that would require further con</li> </ul>		E below);				
(b) They raise the issue of new matter (see NOTE belo						
(c) They are not deemed to place the application in bet	ter form for appeal by materially red	lucing or simplifying t	ne issues for			
appeal; and/or	corresponding number of finally rais	oted alaima				
(d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: See Continuation Sheet. (See 37 CFR 1.116 and 41.33(a)).						
		mpliant Amondment /	DTOL 324)			
4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).						
<ol> <li>Applicant's reply has overcome the following rejection(s):</li> <li>Would be allowable if submitted in a separate, timely filed amendment canceling the</li> </ol>						
non-allowable claim(s).	iowabie ii subiliitted iii a separate, t	intery filed afficilities	it cancelling the			
7. Tor purposes of appeal, the proposed amendment(s): a)		be entered and an e	xplanation of			
how the new or amended claims would be rejected is prov						
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed:						
Claim(s) objected to:						
Claim(s) rejected: <u>14-20</u> . Claim(s) withdrawn from consideration:						
AFFIDAVIT OR OTHER EVIDENCE						
<ol> <li>The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and</li> </ol>						
was not earlier presented. See 37 CFR 1.116(e).						
<ol> <li>The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to c showing a good and sufficient reasons why it is necessan</li> </ol>	vercome <u>all</u> rejections under appea	l and/or appellant fail	s to provide a			
10. The affidavit or other evidence is entered. An explanatio						
REQUEST FOR RECONSIDERATION/OTHER						
<ol> <li>The request for reconsideration has been considered but</li> </ol>	t does NOT place the application in	condition for allowan	ce because:			
12. Note the attached Information Disclosure Statement(s).	(DTO/SB/08) Paper No/e)					
<ol> <li>Invote the attached information Disclosure Statement(s).</li> <li>It is not the attached information Disclosure Statement(s).</li> </ol>	(F 10/35/00) Papel NO(8).					
	/Elizabeth C. Kemmerer	,				

Primary Examiner, Art Unit 1646

## Continuation Sheet (PTOL-303)

Application No.

Continuation of 3. NOTE: First, additional consideration under 35 U.S.C. 112, 2 paragraph would have to be given to the inclusion of trademarks in the claims. Second, the amendment of the claims to recite "malignant" (claims 14 and 19) and the specific analogs would require further search and consideration.

Continuation of 13. Other: If the amendment were entered, the rejection of claims 14 and 19 under 35 U.S.C. 102(b) would be overcome. In addition, Applicants have narrowed the claims to recite certain GnRH analogs thus addressing the issues raised in the Office action mailed 3 August 2007.